FHITlow/pHER2high signature in non‐small cell lung cancer is predictive of anti‐HER2 molecule efficacy
- 1 April 2020
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 251 (2) , 187-199
Abstract
Despite its efficacy in solid tumours, in particular HER2+ breast cancer, HER2‐targeted therapy has given rise to disappointing results in non‐small cell lung cancer (NSCLC). With the aim of refining the target population for anti‐HER2 therapies in NSCLC, we investigated the relationships between HER2 and the tumour suppressor fragile histidine triad (FHIT) in lung tumour cells. First, we observed a negative correlation between FHIT expression and the activated form of HER2 (pHER2) in NSCLC samples and in lung tumour cell lines. Moreover, the silencing or overexpression of FHIT in lung cell lines led to an increase or decrease of HER2 activity, respectively. We also demonstrated that two anti‐HER2 drugs, irbinitinib and trastuzumab, restore a more epithelial phenotype and counteract cell invasiveness and growth of FHIT‐silenced tumour cell lines. Finally, we showed that the FHITlow/pHER2high phenotype predicts sensitivity to an anti‐HER2 therapy in primary tumour cells from NSCLC patients. Our results show that FHIT regulates the activity of HER2 in lung tumour cells and that FHIT‐inactivated tumour cells are sensitive to HER2 inhibitors. A new subclass of patients with NSCLC may be eligible for an anti‐HER2 therapy. © 2020 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.Keywords
Funding Information
- Ligue Contre le Cancer
This publication has 38 references indexed in Scilit:
- Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer modelsFrontiers in Pharmacology, 2013
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancerNature Genetics, 2012
- Targeting the EGFR signaling pathway in cancer therapyExpert Opinion on Therapeutic Targets, 2012
- Targeted therapy in non-small-cell lung cancer—is it becoming a reality?Nature Reviews Clinical Oncology, 2010
- Fhit regulates invasion of lung tumor cellsOncogene, 2009
- The International Epidemiology of Lung Cancer: Geographical Distribution and Secular TrendsJournal of Thoracic Oncology, 2008
- The tumor suppressor Fhit acts as a repressor of β-catenin transcriptional activityProceedings of the National Academy of Sciences, 2007
- Fhit Expression Protects Against HER2-Driven Breast tumor Development: Unraveling the Molecular InterconnectionsCell Cycle, 2007
- FHIT-proteasome degradation caused by mitogenic stimulation of the EGF receptor family in cancer cellsProceedings of the National Academy of Sciences, 2006
- Association of HER‐2 overexpression with prognosis in nonsmall cell lung carcinoma: A metaanalysisCancer, 2005